1. Home
  2. RLMD vs GMM Comparison

RLMD vs GMM Comparison

Compare RLMD & GMM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RLMD
  • GMM
  • Stock Information
  • Founded
  • RLMD 2004
  • GMM 2017
  • Country
  • RLMD United States
  • GMM China
  • Employees
  • RLMD N/A
  • GMM N/A
  • Industry
  • RLMD Biotechnology: Pharmaceutical Preparations
  • GMM
  • Sector
  • RLMD Health Care
  • GMM
  • Exchange
  • RLMD Nasdaq
  • GMM Nasdaq
  • Market Cap
  • RLMD 53.4M
  • GMM 61.9M
  • IPO Year
  • RLMD N/A
  • GMM 2023
  • Fundamental
  • Price
  • RLMD $1.59
  • GMM $1.92
  • Analyst Decision
  • RLMD Buy
  • GMM
  • Analyst Count
  • RLMD 3
  • GMM 0
  • Target Price
  • RLMD $5.00
  • GMM N/A
  • AVG Volume (30 Days)
  • RLMD 1.6M
  • GMM 641.0K
  • Earning Date
  • RLMD 11-06-2025
  • GMM 08-18-2025
  • Dividend Yield
  • RLMD N/A
  • GMM N/A
  • EPS Growth
  • RLMD N/A
  • GMM N/A
  • EPS
  • RLMD N/A
  • GMM 1.79
  • Revenue
  • RLMD N/A
  • GMM $48,171,048.00
  • Revenue This Year
  • RLMD N/A
  • GMM N/A
  • Revenue Next Year
  • RLMD N/A
  • GMM N/A
  • P/E Ratio
  • RLMD N/A
  • GMM $1.23
  • Revenue Growth
  • RLMD N/A
  • GMM 41.74
  • 52 Week Low
  • RLMD $0.24
  • GMM $1.69
  • 52 Week High
  • RLMD $3.98
  • GMM $15.60
  • Technical
  • Relative Strength Index (RSI)
  • RLMD 74.57
  • GMM 26.10
  • Support Level
  • RLMD $1.44
  • GMM $2.11
  • Resistance Level
  • RLMD $1.72
  • GMM $3.24
  • Average True Range (ATR)
  • RLMD 0.24
  • GMM 0.19
  • MACD
  • RLMD 0.05
  • GMM -0.00
  • Stochastic Oscillator
  • RLMD 86.90
  • GMM 3.66

About RLMD Relmada Therapeutics Inc.

Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.

About GMM Global Mofy Metaverse Limited

Global Mofy AI Ltd operates as a technology solutions provider engaged in virtual content production, digital marketing, and digital assets development for the metaverse industry. It utilizes its proprietary Mofy Lab technology platform which consists of three-dimensional (3D) rebuilt technology and artificial intelligence (AI) interactive technology to create a 3D high-definition virtual version of a wide range of physical world objects such as human, animal, and scenes which can be used in different applications.

Share on Social Networks: